---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-221677"
form_type: "8-K"
ticker: "TNGX"
cik: "0001819133"
company_name: "Tango Therapeutics, Inc."
filed_at: "2026-05-13T20:16:36+00:00"
generated_at: "2026-05-13T21:53:49.332439+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Tango Therapeutics Q1 net loss $45.5M; cash $379.8M; board resignations; vopimetostat combo data due 2026

## Summary
- Net loss $45.5M ($0.32/sh) vs $39.9M ($0.36/sh) YoY; R&D $33.5M, G&A $15.2M.
- Cash $379.8M as of March 31, 2026; runway into 2028.
- Directors Alexis Borisy and Kanishka Pothula resigned May 13; Sung Lee takes Lead Independent Director and Compensation Chair.
- Initial phase 1/2 data for vopimetostat + RAS(ON) inhibitors expected in 2026; registrational path being reviewed.
- New leadership appointments: Matthew Gall as CFO, Yen-Ching Chua as CDOO, Janice Kapty as SVP Corp Strategy (April 2026).

## SEC filing metadata
- accession: 0001193125-26-221677
- form_type: 8-K
- ticker: TNGX
- cik: 0001819133
- company_name: Tango Therapeutics, Inc.
- filed_at: 2026-05-13T20:16:36+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819133/000119312526221677/0001193125-26-221677-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819133/000119312526221677/tngx-20260513.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-221677
- JSON: https://secwatch.observer/filing/0001193125-26-221677.json
- Plain text: https://secwatch.observer/filing/0001193125-26-221677.txt

## Key facts
- Executive change
  Kanishka Pothula resigned as Director, Member of the Nominating and Corporate Governance Committee at Tango Therapeutics, Inc..
  - Action: resigned
  - Role: Director, Member of the Nominating and Corporate Governance Committee
  source text: Also on May 12, 2026, Kanishka Pothula resigned from the Board and as a member of the Nominating and Corporate Governance Committee of the Board (the “NCG Committee”), in each case effective as of May 13, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1819133/000119312526221677/0001193125-26-221677-index.htm
- Executive change
  Sung Lee was appointed as Lead Independent Director, Chairperson of the Compensation Committee, Member of NCG Committee at Tango Therapeutics, Inc..
  - Action: appointed
  - Role: Lead Independent Director, Chairperson of the Compensation Committee, Member of NCG Committee
  source text: the Board appointed Sung Lee as Lead Independent Director of the Board and the Chairperson of the Compensation Committee and as a member thereof, each effective as of May 13, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1819133/000119312526221677/0001193125-26-221677-index.htm
- Executive change
  Alexis Borisy resigned as Director, Lead Independent Director, Chairperson of the Compensation Committee at Tango Therapeutics, Inc..
  - Action: resigned
  - Role: Director, Lead Independent Director, Chairperson of the Compensation Committee
  source text: On May 12, 2026, Alexis Borisy resigned from the Company’s Board of Directors (the “Board”), as Lead Independent Director of the Board, and as the Chairperson of the Compensation Committee of the Board (the “Compensation Committee”) and as a member thereof, in each case effective as of May 13, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1819133/000119312526221677/0001193125-26-221677-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.